- Home
- ERIE vs AXSM Comparison
ERIE vs AXSM Comparison
Compare ERIE & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERIE | AXSM |
|---|---|---|
| Founded | 1925 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 12.0B |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ERIE | AXSM |
|---|---|---|
| Price | $239.00 | $244.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $211.12 |
| AVG Volume (30 Days) | 171.7K | ★ 688.7K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 491.00 | N/A |
| Revenue | ★ $1,691,774,000.00 | N/A |
| Revenue This Year | $6.83 | $57.24 |
| Revenue Next Year | N/A | $55.88 |
| P/E Ratio | $0.47 | ★ N/A |
| Revenue Growth | ★ 5.96 | N/A |
| 52 Week Low | $204.63 | $96.09 |
| 52 Week High | $380.67 | $260.19 |
Technical Indicators
Market Signals| Indicator | ERIE | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 57.82 |
| Support Level | $237.15 | $148.87 |
| Resistance Level | $253.33 | $260.19 |
| Average True Range (ATR) | 7.47 | 8.32 |
| MACD | 1.67 | -2.17 |
| Stochastic Oscillator | 97.57 | 42.19 |
Price Performance
Historical ComparisonAbout ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.